Eli Lilly Warns of Job Cuts at Irish Plant
One of Ireland’s largest pharmaceutical companies has warned of job losses at its Kinsale plant if the EU does not exempt it from a forthcoming ban on a carcinogenic chemical.
Eli Lilly, a US multinational with 800 employees in Ireland, uses the chemical to produce raloxifene, marketed as Evista, a prescription drug to prevent osteoporosis in post-menopausal women. The drug is currently used by 1.7 million patients worldwide.
Ethylene dichloride (EDC) will be banned within the EU from November next year but the company has applied for a 12-year derogation, or exemption, as it has yet to identify a “technically
Eli Lilly, a US multinational with 800 employees in Ireland, uses the chemical to produce raloxifene, marketed as Evista, a prescription drug to prevent osteoporosis in post-menopausal women. The drug is currently used by 1.7 million patients worldwide.
Ethylene dichloride (EDC) will be banned within the EU from November next year but the company has applied for a 12-year derogation, or exemption, as it has yet to identify a “technically